Nairouz Elgeioushi

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Johanna C. Bendell, Patricia LoRusso, Michael J. Overman et al. · Cancer Immunology Immunotherapy · 2023 · 109 citations · Full text

Medicine, Oncology, Pharmacology +17

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

Avram Goldberg, T D Geppert, Elena Schiopu et al. · Arthritis Research & Therapy · 2014 · 99 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily et al. · Clinical Cancer Research · 2020 · 55 citations · Full text

Medicine, Oncology, Pharmacology +7

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

Johanna C. Bendell, Patricia LoRusso, Michael J. Overman et al. · Journal of Clinical Oncology · 2021 · 39 citations

Medicine, Immunology, Oncology +17

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Jeffrey R. Infante, Sanjay Goel, H. Burris et al. · Journal for ImmunoTherapy of Cancer · 2019 · 31 citations · Full text

Pharmacy, Oncology, Pharmacology +17